

## MIGRAINE ACUTE TREATMENT AGENTS PRIOR AUTHORIZATION FORM (form effective 1/3/2022)

Prior authorization guidelines for Migraine Acute Treatment Agents and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at <a href="https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx">https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx</a>.

☐ New request ☐ Renewal request	total # of pages:	Prescriber name:					
Name of office contact:		Specialty:					
Contact's phone number:		NPI:		State license #:			
LTC facility contact/phone:		Street address:					
Beneficiary name:		Suite #:	City/state/zip:				
Beneficiary ID#:	DOB:	Phone:	Fax:				
CLINICAL INFORMATION							
Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred drugs in this class.							
Drug requested:			Streng	Strength & dosage form:			
Dose/directions:			Quanti	ty:	Refills:		
Diagnosis (submit documentation):			Dx cod	Dx code (required):			
Please complete either the INITIAL requests or RENEWAL requests section. If the requested prescription exceeds the quantity limits/daily dose limits, also complete the QUANTITY LIMITS/DAILY DOSE LIMITS section. Please refer to the DHS website at <a href="https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx">https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx</a> for applicable limits.							
INITIAL requests  Check all of the following that apply to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.							
□ For a NON-PREFERRED MIGRAINE ACUTE TREATMENT AGENT □ For a non-preferred TRIPTAN: □ Tried and failed or has a contraindication or an intolerance to the preferred TRIPTANS (refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred triptans in the Migraine Acute Treatment Agents class) □ For ALL OTHER non-preferred Migraine Acute Treatment Agents: □ Tried and failed or has a contraindication or an intolerance to the preferred drugs in this class that are approved or medically accepted for the treatment of the beneficiary's diagnosis (refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred drugs in the Migraine Acute Treatment Agents class)							
For a GEPANT/SMALL MOLECULE CGRP INHIBITOR (e.g., Nurtec ODT, Ubrelvy)  Tried and failed at least 2 triptans (e.g., rizatriptan, sumatriptan, etc.) or has a contraindication or intolerance to triptans							
☐ For a DITAN/5HT1 RECEPTOR AGONIST (e.g., Reyvow) ☐ Tried and failed or has a contraindication or intolerance to the preferred triptans (refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred triptans in the Migraine Acute Treatment Agents class)							
☐ For an ERGOT ALKALOID (e.g., Cafergot, D.H.E., Migranal, etc.) ☐ Tried and failed or has a contraindication or intolerance to the following: ☐ caffeine/analgesic combination (e.g., Excedrin) ☐ NSAIDs							



Office of Medical Assistance Programs Fee-for-Service, Pharmacy Division Phone 1-800-537-8862 Fax 1-866-327-0191

☐ triptans						
a combination of an NSAID with a triptan						
<u> </u>						
other:						
RENEWAL	requests					
Has the beneficiary experienced an improvement in headache pain, symptoms, and/ or duration since						
starting the requested medication?			Submit documentation.			
starting the requested medication.		□No				
QUANTITY LIMITS/DAILY	DOSE LIMITS requests					
All requests that exceed the quantity limits/daily dose limits established by DHS require prior authorization.						
Please refer to the DHS website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-						
<u>Limits.aspx</u> for applicable limits.						
Is the requested medication prescribed by a neurologist or specialist certified	l in headache medicine hy	□Yes				
Is the requested medication prescribed by a neurologist or specialist certified in headache medicine by the United Council for Neurologic Subspecialties (UCNS)?						
the office Council for Neurologic Subspecialities (OCNS)?		□No				
Is the requested quantity/dose/frequency supported by current medical comp	pendia and/or peer-	□Yes				
reviewed medical literature?			Submit documentation.			
For ACUTE TREATMENT OF MIGRAINE, check all that apply to the bene	eficiary and this request a	nd SUBMI	T DOCUMENTATION for each:			
Was evaluated for the overuse of abortive headache medications (e.g., opioids, triptans, butalbital, etc.)						
☐Will be using the requested medication with <u>at least one</u> medication for migraine prevention – specify:						
anticonvulsant (e.g., topiramate, valproate derivative) beta blocker (e.g.		metoprolol, propranolol, timolol)				
antidepressant (e.g., SNRI, TCA)	□CRGP monoclonal a	antibody (e.g., Aimovig, Ajovy, Emgality)				
other:						
☐ Tried and failed preventive migraine medications – specify:						
☐ anticonvulsant (e.g., topiramate, valproate derivative) ☐ beta blocker (e.g., n			ropranolol, timolol)			
antidepressant (e.g., SNRI, TCA)		CRGP monoclonal antibody (e.g., Aimovig, Ajovy, Emgality)				
other:	_	, ,	3. 3. 3. 3.			
Has an intolerance or a contraindication to preventive migraine medication	ns – specify:					
anticonvulsant (e.g., topiramate, valproate derivative) beta blocker (e.g., r			ropranolol, timolol)			
antidepressant (e.g., SNRI, TCA)	_	CRGP monoclonal antibody (e.g., Aimovig, Ajovy, Emgality)				
other:	_	J ( )	3. 3. 3.			
PLEASE <u>FAX</u> COMPLETED FORM WITH <u>REQUIRED CLINICAL DOCUMENTATION</u> TO DHS – PHARMACY DIVISION						
Prescriber Signature:		Date:				

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.